John Nieland

Company: 2N Pharma

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Leveraging Biomarkers to Understand Mitochondrial Dysfunction in ALS: A Neuro-Metabolic Approach 1:30 pm

Exploring biomarkers reflecting mitochondrial energy imbalance in ALS with a focus on shifts from glucose to lipid oxidation Discussing early-stage biomarkers identified in ALS animal models (days 20-25), allowing for earlier detection of disease progression Showcasing preclinical data on metabolic interventions that restore glucose oxidation highlighting biomarkers used to monitor treatment effects Clinical data Expanding…Read more

day: Conference Day Two Track A PM